Experts on prostate cancer discuss how treatment has evolved over the years, focusing on doublet and triplet therapy and their utility.
Study finds disparities in management of mCSPC
April 17th 2024“These findings suggest that guideline recommended treatment intensification remains low for patients with mCSPC in both Medicare and the Veterans Health Administration, but especially for Black patients,” says Daniel J. George, MD.